Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association

Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association

Ridgetech, Inc. (Nasdaq: RDGT ) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that its wholly owned offline pharmaceutical wholesale distribution platform, Zhejiang Jiuxin Medicine Co., Ltd. ("Jiuxin Medicine"), has been elected as a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association (the "Association"), which is scheduled to be officially inaugurated on July 28, 2026. The appointment reflects industry recognition of Jiuxin Medicine's efforts to advance pharmaceutical supply chain transparency and its pioneering implementation of full-variety drug traceability code scanning across Zhejiang Province.

Association Mandate and Industry Recognition The Association was established to promote the high-quality development of the regional biomedical sector, encompassing pharmaceuticals, medical devices, and cosmetics. In March 2026, a delegation of officials and regulators from the Zhejiang Medical Products Administration (the "MPA") conducted an on-site inspection of Jiuxin Medicine to assess the operational effectiveness of its full-variety drug traceability code scanning initiative, gather feedback from pharmaceutical manufacturers, and facilitate cross-sector collaboration on the development of province-wide traceability infrastructure. During the visit, the MPA recognized Jiuxin Medicine's progress in implementing the initiative and encouraged continued collaboration to further enhance the intelligence and efficiency of traceability management while balancing regulatory compliance with operational efficiency.

Technology-Enabled Distribution Excellence Under Ridgetech's dual-engine strategic framework, Jiuxin Medicine and Allright (Hangzhou) Internet Technology Co., Ltd. ("Allright"), the Company's online pharmaceutical and healthcare products distribution platform, serve as two core growth pillars. Jiuxin Medicine primarily focuses on B2B pharmaceutical distribution and supply chain solutions, while strategically collaborating with Allright to advance the integration of Ridgetech's pharmaceutical and healthcare ecosystem. In its operations, Jiuxin Medicine leverages AI-enabled technologies and big-data analytics in conjunction with the drug traceability code system to enhance real-time visibility across the distribution process, enabling timely and accurate identification, interception, and traceability of pharmaceutical products when necessary. The Company is also actively exploring opportunities to leverage traceability data to identify transportation and distribution bottlenecks in real time, with the goal of optimizing efficiency across the broader supply chain network.

Policy Context: The National Drug Traceability Reform Zhejiang Province is among China's pioneering regions in advancing comprehensive drug traceability reform. Through the implementation of full-variety drug traceability code scanning, Zhejiang has taken a leading role in establishing a traceability framework designed to cover the full lifecycle of pharmaceutical products. The drug traceability code is a unique electronic identifier assigned to individual pharmaceutical packages, enabling relevant parties to record and track the movement of products throughout the supply chain. The traceability framework requires key stages of the pharmaceutical lifecycle—including manufacturer shipment, wholesale receipt and outbound distribution, retail pharmacy and hospital receipt, and dispensing—to be recorded through traceability code scanning. In applicable scenarios, successful traceability code scanning is linked to medical insurance settlement under the "payment based on code" mechanism. Under the national drug traceability reform roadmap, full traceability data uploads became mandatory for designated healthcare providers effective January 1, 2026.

Management Commentary Mr. ...